|
|
![]() |
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
|||||||||||||||||||||||||||||||||||||||||||||
| 1 | Conditions listed in this trial | ||||
| Fibrosis | |||||
| Radiation Injuries | |||||
| 2 | More general conditions related to this trial | ||||
| Disorders of Environmental Origin | |||||
| Pathologic Processes | |||||
| Wounds and Injuries | |||||
| 3 | Interventions listed in this trial | ||||
| pentoxifylline | |||||
| 4 | More general drug interventions related to this trial | ||||
| Antioxidants | |||||
| Cardiovascular Agents | |||||
| Enzyme Inhibitors | |||||
| Free Radical Scavengers | |||||
| Hematologic Agents | |||||
| Molecular Mechanisms of Pharmacological Action | |||||
| Pharmacologic Actions | |||||
| Phosphodiesterase Inhibitors | |||||
| Physiological Effects of Drugs | |||||
| Platelet Aggregation Inhibitors | |||||
| Protective Agents | |||||
| Radiation-Protective Agents | |||||
| Therapeutic Uses | |||||
| Vasodilator Agents | |||||
| 5 | Sponsors listed in this trial | ||||
| National Cancer Institute (NCI) | |||||